Thea Pharma Announces the US Launch of Glaucoma Drug Iyuzeh

Thea Pharma announced the launch and availability of Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh, which received FDA approval in December 2022, is the first and only preservative-free latanoprost for patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT) in the US.

“The US launch of Iyuzeh is a major step forward for Théa Group, the eye care community, and patients,” Jean-Frédéric Chibret, President of Théa, said in a company news release. “Glaucoma is a chronic eye disease that affects the everyday lives of more than 60 million people globally. With Iyuzeh now available, eye care providers can effectively treat their POAG and OHT patients with preservative-free latanoprost. I would like to thank everyone involved in achieving this milestone – including the providers and patients who participated in the clinical studies, our teams, and each of our partners – for helping us deliver on our commitment to enable patients access to medication without preservatives.”

In randomized, controlled clinical trials of patients with POAG or OHT with mean baseline IOP of 19-24 mmHg, Iyuzeh lowered IOP by 3 - 8 mmHg compared to 4 - 8 mmHg by Xalatan. [2-4}

Preservative-free latanoprost, launched over 10 years ago, is available in 46 countries, mostly under the brand name Monoprost, with about 1.5 million patients treated monthly.[1] 

Iyuzeh is available for as little as $60 for a 30-day supply through programs with PhilRx and the Thea Savings Card. 

• PhilRx is a service that provides a convenient way to prescribe IYUZEH, with the medication shipped for free and directly to a patient’s door. This service offers online and phone support for both eye care professionals and their patients.
• The Thea Savings Card is available to those commercially insured and not enrolled in a state or federally funded program. A patient may check their eligibility and activate this savings card at activatethecard.com/theasavingscard. Whether a physical or digital card, it can be utilized or redeemed at any retail pharmacy in the U.S.

For more information and eligibility requirements, visit iyuzeh.com. 

References:

1. Théa. Data on file. 2023.
2. IYUZEH™ (latanoprost ophthalmic solution) 0.005%. Prescribing information. Thea Pharma Inc; 2022.
3. Bacharach J, Ahmed IIK, Sharpe ED, Korenfeld MS, Zhang S, Baudouin C. Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial. Clin Ophthalmol. 2023;17:2575-2588. https://doi.org/10.2147/OPTH.S414015.
4. Rouland JF, Traverso CE, Stalmans I, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013;97(2):196–200. doi:10.1136/bjophthalmol-2012-302121.